Review article · 2022 · Open access

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

Rui Li, Miao Liu, Zhenya Yang, Jiao Li, Yuxin Gao, Ruirong Tan

Molecules, 27(24), 8828 · Published 12 December 2022 · DOI 10.3390/molecules27248828

Open PDFView at the publisherCite this paper

In brief

“Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future” is a 2022 review article by Rui Li and 5 co-authors, published in Molecules. OpenAlex counts 75 citations as of 19 November 2026, which puts it in the top 2% of works published in 2022 by citations. It is open access under a CC BY licence: the full text is free to read at Molecules.

Citations
75
Most cited in
2025 (37)
Field-weighted impact
1.46
References
95
Authors
6

Abstract

The PROteolysis TArgeting Chimeras (PROTACs) is an innovative technique for the selective degradation of target proteins via the ubiquitin-proteasome system. Compared with traditional protein inhibitor drugs, PROTACs exhibit advantages in the efficacy and selectivity of and in overcoming drug resistance in cancer therapy, providing new insights into the discovery of anti-cancer drugs. In the last two decades, many PROTAC molecules have been developed to induce the degradation of cancer-related targets, and they have been subjected to clinical trials. Here, we comprehensively review the historical milestones and latest updates in PROTAC technology. We focus on the structures and mechanisms of PROTACs and their application in targeting tumor-related targets. We have listed several representative PROTACs based on CRBN, VHL, MDM2, or cIAP1 E3 ligases, and PROTACs that are undergoing anti-cancer clinical trials. In addition, the limitations of the current research, as well as the future research directions are described to improve the PROTAC design and development for cancer therapy.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Li, R., Liu, M., Yang, Z., Li, J., Gao, Y., & Tan, R. (2022). Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future. Molecules, 27(24), 8828. https://doi.org/10.3390/molecules27248828

MLA 9

Li, Rui, et al. “Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.” Molecules, vol. 27, no. 24, 2022, p. 8828. https://doi.org/10.3390/molecules27248828.

Chicago

Li, Rui, Miao Liu, Zhenya Yang, Jiao Li, Yuxin Gao, and Ruirong Tan. 2022. “Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.” Molecules 27 (24): 8828. https://doi.org/10.3390/molecules27248828.

Harvard

Li, R. et al. (2022) ‘Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future’, Molecules, 27(24), p. 8828. doi:10.3390/molecules27248828.

IEEE

R. Li, M. Liu, Z. Yang, J. Li, Y. Gao, and R. Tan, “Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future,” Molecules, vol. 27, no. 24, p. 8828, 2022, doi: 10.3390/molecules27248828.

BibTeX

@article{li2022proteolysis,
  title     = {{Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future}},
  author    = {Li, Rui and Liu, Miao and Yang, Zhenya and Li, Jiao and Gao, Yuxin and Tan, Ruirong},
  journal   = {Molecules},
  year      = {2022},
  volume    = {27},
  number    = {24},
  pages     = {8828},
  doi       = {10.3390/molecules27248828},
  url       = {https://doi.org/10.3390/molecules27248828}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202377
20241818
20253737
20261212

Its field-weighted citation impact is 1.46: it has been cited 1.46 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors

  • PROTACs
  • protein degradation
  • ubiquitin-proteasome system
  • cancer therapy
  • drug resistance
  • cereblon
  • VHL
  • MDM2

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Li, R., Liu, M., Yang, Z., Li, J., Gao, Y., & Tan, R. (2022). Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future. Molecules, 27(24), 8828. https://doi.org/10.3390/molecules27248828

How many times has this paper been cited?

75 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Molecules: sign in and open the PDF from this page.

Who wrote this paper?

Rui Li, Miao Liu, Zhenya Yang, Jiao Li, Yuxin Gao, Ruirong Tan.

What is the DOI of this paper?

10.3390/molecules27248828, permanently at https://doi.org/10.3390/molecules27248828. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.